mProX™ Human CD40LG Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD40LG, the ligand for the CD40 receptor, has various applications in different fields. In chronic inflammatory diseases, the soluble CD40 receptor (sCD40) isoform generated by proteolytic cleavage or alternative splicing of CD40 is implicated in the pathogenesis of these diseases. It is also considered a potential biomarker for chronic inflammatory diseases. In people living with HIV, high levels of soluble CD40 ligand (sCD40L) are associated with metabolic syndrome, a condition characterized by endothelial dysfunction. This suggests a potential role for sCD40L in the association between cardiometabolic comorbidity and HIV infection. In patients with complex regional pain syndrome (CRPS), inflammation induces the expression of α(1)-adrenoceptor in peripheral blood mononuclear cells (PBMC). This inflammatory cascade, along with elevated levels of IL-6, may contribute to systemic inflammation and antibody production in CRPS. Additionally, CD40 ligand is investigated as a potential adjuvant for the development of an efficient HIV-1 therapeutic vaccine. The linkage of CD40L to the Nef antigen can induce the Th-1 pathway and activate cytotoxic T lymphocytes. Finally, in Parkinson's disease, abnormal B-lymphocyte immune responses in peripheral blood, including alterations in B-cell subsets and increased production of cytokines, are associated with the development of the disease. Elevated levels of soluble CD40 ligand, along with other cytokines, may serve as potential targets for intervention in Parkinson's disease.